Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type. ~' e/ r9 D0 i2 n% ~
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9 & A2 l% D6 d. T% A9 J+ t
+ Author Affiliations, y6 q8 V3 I. i8 M( T
5 r; f) V0 ?! }* a% H6 Z: w1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2 X5 Z$ X* s8 r7 H ~2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
- H) D; q- g+ a4 }# p3 H. U1 P9 F) ?3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan " |8 b( K" Y' N0 Z
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
' o9 B: d, T+ x0 E. {1 n0 l- b5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 2 S0 M% o" A5 F7 {4 g
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan 5 w+ `. {4 H& S$ x9 }9 i, G
7Kinki University School of Medicine, Osaka 589-8511, Japan 5 ^5 S X6 ]( F$ ~$ a( ^- ~ T
8Izumi Municipal Hospital, Osaka 594-0071, Japan ' N9 L' c7 K8 O1 d* n
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
e, ^: C8 s/ }6 I9 M* {9 pCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
5 |( n5 {& @3 C% M/ AAbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
8 [; I" n3 t" f# M% Y- n( ~9 H8 \$ m t/ J8 a- o; I
|